Why might visit-to visit variability of lipoproteins have an effect on cardiovascular events?

[1]  Shouling Wu,et al.  Visit-to-visit variability of lipid measurements and the risk of myocardial infarction and all-cause mortality: A prospective cohort study. , 2020, Atherosclerosis.

[2]  J. Siller-Matula,et al.  Medication adherence and its determinants in patients after myocardial infarction , 2020, Scientific Reports.

[3]  W. Dai,et al.  Visit-to-visit blood pressure variability and risk of chronic kidney disease: A systematic review and meta-analyses , 2020, PloS one.

[4]  M. Bennie,et al.  Real‐world evaluation of the impact of statin intensity on adherence and persistence to therapy: A Scottish population‐based study , 2020, British journal of clinical pharmacology.

[5]  Jun Gu,et al.  Visit-to-visit variability in low-density lipoprotein cholesterol is associated with adverse events in non-obstructive coronary artery disease , 2019, Anatolian journal of cardiology.

[6]  Songzhu Zhao,et al.  Visit-to-Visit Glycemic Variability and Risks of Cardiovascular Events and All-Cause Mortality: The ALLHAT Study , 2019, Diabetes Care.

[7]  G. Watts,et al.  Effects of medication, treatment, and behavioral beliefs on intentions to take medication in patients with familial hypercholesterolemia. , 2018, Atherosclerosis.

[8]  Hun‐Sung Kim,et al.  Cholesterol variability and the risk of mortality, myocardial infarction, and stroke: a nationwide population-based study , 2017, European heart journal.

[9]  P. Barter,et al.  Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin, and simvastatin: results from VOYAGER. , 2016, European heart journal. Cardiovascular pharmacotherapy.

[10]  B. Nordestgaard,et al.  Negative statin-related news stories decrease statin persistence and increase myocardial infarction and cardiovascular mortality: a nationwide prospective cohort study. , 2016, European heart journal.

[11]  J. Tomassini,et al.  Variability of the LDL-C lowering response to ezetimibe and ezetimibe + statin therapy in hypercholesterolemic patients. , 2015, Atherosclerosis.

[12]  Ž. Reiner,et al.  Adverse effects of statins - myths and reality. , 2015, Current pharmaceutical design.

[13]  J. Blacher,et al.  Prognostic Significance of Visit‐to‐Visit Systolic Blood Pressure Variability: A Meta‐Analysis of 77,299 Patients , 2015, Journal of clinical hypertension.

[14]  Ž. Reiner.  Resistance and intolerance to statins. , 2014, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[15]  Ž. Reiner.  Statins in the primary prevention of cardiovascular disease , 2013, Nature Reviews Cardiology.

[16]  N. Kressin,et al.  A pilot study identifying statin nonadherence with visit-to-visit variability of low-density lipoprotein cholesterol. , 2013, The American journal of cardiology.

[17]  Ruiping Huang,et al.  Effect of statins on cholesterol crystallization and atherosclerotic plaque stabilization. , 2011, The American journal of cardiology.

[18]  Ž. Reiner,et al.  Physicians' perception, knowledge and awareness of cardiovascular risk factors and adherence to prevention guidelines: the PERCRO-DOC survey. , 2010, Atherosclerosis.

[19]  Wan Zhang,et al.  Short-term withdrawal of simvastatin induces endothelial dysfunction in patients with coronary artery disease: a dose-response effect dependent on endothelial nitric oxide synthase. , 2009, International journal of cardiology.

[20]  Chi‐Hang Lee,et al.  Visit-to-visit variability in LDL- and HDL-cholesterol is associated with adverse events after ST-segment elevation myocardial infarction: A 5-year follow-up study. , 2016, Atherosclerosis.